HOW IT WORKS:
In Silico → In Vitro → In Vivo Flywheel
CellRep’s platform is composed of an end-to-end pipeline, from in silico target and compound discovery to preclinical validation.
In Silico
Target Discovery
Compound Discovery
In Vitro
Compound Validation
The In Silico results are shared with the In Vitro team, and then these results are translated to In vivo models.
All this information feeds back to the In Silico team, who adjusts their approach for the next cycle.
Latest Discoveries
Examples of how dysfunctional T cells can be reprogrammed ex vivo and in vivo to increase their antiviral capacity against chronic viral infection.
In collaboration with Baylor College of Medicine, we tested a candidate compound with the CAR-T cells against breast cancer. CAR-T cells pre-treated with our compound had an increase in their antitumor capacity, compared with untreated CAR-T cells (see the % of residual tumor cells [red quadrant] reduced 2-fold).
Join us in revolutionizing how we treat disease and age
Our papers
Examples of how dysfunctional T cells can be reprogrammed ex vivo and in vivo to increase their antiviral capacity against chronic viral infection.
This is a little glimpse of our science.
